Clinical trial · no report yet · Phase 2
CARTITUDE-2
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
- NCT04133636 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- 60 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 28 | |
| Podcasts | 18 | |
| X threads | 14 |
The trial
ClinicalTrials.gov- Official title
- 68284528MMY2003: A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
- Phase
- Phase 2
- Status
- Active not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- JNJ-68284528; Lenalidomide; Daratumumab; Bortezomib; Dexamethasone
- Arms
- JNJ-68284528 · Experimental
- Enrollment
- 208
- Primary outcomes
- Cohorts A, B, C, D, E, and F: Percentage of Participants with Negative Minimal Residual Disease (MRD)
- For US sites only: Cohort G: Percentage of Participants with Sustained MRD Negative Complete Response (CR)
- Sponsor
- Janssen Research & Development, LLC
- Start
- Nov 7, 2019
- Primary completion
- Feb 26, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04133636 · updated Sep 25, 2026
Publications
linked from the registry- Cohen AD, Mateos MV, Cohen YC, Rodriguez-Otero P, Paiva B, van de Donk NWCJ, Martin T, Suvannasankha A, De Braganca KC, Corsale C, Schecter JM, Varsos H, Deraedt W, Wang L, Vogel M, Roccia T, Xu X, Mistry P, Zudaire E, Akram M, Nesheiwat T, Pacaud L, Avivi I, San-Miguel J. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023 Jan 19;141(3):219-230. doi: 10.1182/blood.2022015526. PubMed 36095849